Anti-inflammatory peptides and composition comprising the same
US-9540419-B2 · Jan 10, 2017 · US
Anti-inflammatory peptides and composition comprising the same
US12156902B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12156902-B2 |
| Application number | US-202318446712-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 9, 2023 |
| Priority date | May 11, 2012 |
| Publication date | Dec 3, 2024 |
| Grant date | Dec 3, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method of treating bone, joint, muscle, and connective tissue related inflammatory disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating bone, joint, muscle and connective tissue related inflammatory disease comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1 wherein the bone, joint, muscle and connective tissue related inflammatory disease is eosinophilic granuloma, arthritis, arthralgia, osteomyelitis, dermatomyositis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, or synovitis. 2. The method of claim 1 , wherein the composition is administered orally, rectally, transdermally, intravenously, intramuscularly, intraperitoneally, in the bone marrow, epidurally, or subcutaneously. 3. The method of claim 1 , wherein the composition comprises the isolated peptide at a concentration of 0.1 μg/mg to 1 mg/mg. 4. The method of claim 1 , wherein the composition is administered in a single dose and the isolated peptide in the single dose is at a concentration of 0.1 μg/kg to 1.0 g/kg body weight of the subject. 5. The method of claim 1 , wherein the composition is administered in a single dose and the isolated peptide in the single dose is at a concentration of 1 μg/kg to 10 mg/kg body weight of the subject. 6. The method of claim 1 , wherein the composition is administered 1 to 3 times a day. 7. The method of claim 1 , wherein the composition is administered at a daily dose and the isolated peptide in the daily dose is 0.1 μg/kg to 1.0 g/kg body weight of the subject. 8. The method of claim 1 , wherein the composition is administered 1 to 3 times daily.
Assignees
Inventors
Classifications
RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Peptides; Protein hydrolysates · CPC title
Inhibitors; Suppressors · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12156902B2 cover?
- The present invention relates to a method of treating bone, joint, muscle, and connective tissue related inflammatory disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.
- Who is the assignee on this patent?
- Gemvax & Kael Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N9/1276. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).